Evotec SE (EVO) Net Income towards Common Stockholders Growth (1y) (2010 - 2025)
Evotec SE (EVO) Net Income towards Common Stockholders Growth (1y) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Evotec SE | 339.17 Mn | 338.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42.50% |
| Sep 30, 2025 | 15.74% |
| Dec 31, 2024 | -131.96% |
| Sep 30, 2024 | -240.15% |
| Dec 31, 2023 | 49.69% |
| Sep 30, 2023 | -11.04% |
| Jun 30, 2023 | 53.41% |
| Dec 31, 2022 | -172.84% |
| Sep 30, 2022 | -69.90% |
| Jun 30, 2022 | -141.25% |
| Mar 31, 2022 | -229.31% |
| Dec 31, 2021 | 3,192.96% |
| Sep 30, 2021 | 9,714.16% |
| Dec 31, 2020 | -82.29% |
| Jun 30, 2010 | 1,394.43% |
| Mar 31, 2010 | 445.55% |